Merck & Co to spin off cancer unit ahead of Keytruda patent cliff
By Benjamin Chiou
Date: Monday 23 Feb 2026
(Sharecast News) - US pharma group Merck & Co is set to spin off its oncology operations in an effort to keep its wider healthcare businesses immune from a forthcoming patent cliff for its blockbuster Keytruda drug.
The firm is to split its healthcare business into two units: one housing its cancer portfolio and the other for non-cancer assets across the specialty, pharma and infectious-diseases categories.
"As we advance our pipeline and drive commercial success across an increasingly diversified portfolio, including a growing pipeline across Specialty, Pharma & Infectious Diseases, we are sharpening our focus on delivering innovative medicines for patients and creating long‑term value for our stakeholders," said chair and chief executive Robert Davis in a statement.
The move is thought to be part of a diversification drive as copycat versions of immunotherapy treatment Keytruda come to the market from 2028.
The end of US patent protection is expected to result in a drop in sales of the best-selling prescription drug in the world, which generated $30bn for Merck in 2025 - equal to nearly half of the group's $65bn annual turnover.
The shake-up comes as Joseph Romanelli, currently the head of Merck's Human Health International division, plans to retire, the Wall Street Journal reported.
The new cancer business will be headed up by company exec Jannie Ossthuizien, who was most recently the president of the US human-health arm, while Brian Foard will join from Sanofi as head of the Specialty, Pharma & Infectious Diseases division.
Merck & Co shares were flat at $122.20 by 1529 GMT.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN